대한한방내과학회지 (The Journal of Internal Korean Medicine)

대한한방내과학회 (The Society of Internal Korean Medicine)
권호 표지

항암화학요법과의 순차적, 그리고 병행적 요법으로서의 aRVS 투여로 장기 생존과 좋은 삶의 질을 유지한 전이성 비소세포폐암 증례보고

Case Report : Long-term Survival and Good-Quality of Life in Metastatic Non-small Cell Lung Cancer Patients Treated with Allergen-removed Rhus verniciflua Stokes (aRVS) as Sequential and Concurrent Treatment with Chemotherapy

  • 이진수 (경희대학교 한의과대학 임상종양학과) ;
  • 박형준 (경희대학교 한의과대학 임상종양학과) ;
  • 채진 (경희대학교 한의과대학 임상종양학과) ;
  • 김경석 (강동경희대학교병원 한방내과) ;
  • 정현식 (강동경희대학교병원 한방내과) ;
  • 이상헌 (강동경희대학교병원 한방내과) ;
  • 최원철 (경희대학교 한의과대학 임상종양학과) ;
  • 전성하 (강동경희대학교병원 혈액종양내과)
  • Lee, Jin-Soo (Dept. of Oriental Clinical Oncology, College of Oriental Medicine, Kyung-Hee University) ;
  • Park, Hyeong-Jun (Dept. of Oriental Clinical Oncology, College of Oriental Medicine, Kyung-Hee University) ;
  • Chae, Jean (Dept. of Oriental Clinical Oncology, College of Oriental Medicine, Kyung-Hee University) ;
  • Kim, Kyung-Suk (Dept. of Oriental Internal Medicine, Kyung-Hee University Hospital at Gangdong) ;
  • Jung, Hyun-Sik (Dept. of Oriental Internal Medicine, Kyung-Hee University Hospital at Gangdong) ;
  • Lee, Sang-Hun (Dept. of Oriental Internal Medicine, Kyung-Hee University Hospital at Gangdong) ;
  • Choi, Won-Choel (Dept. of Oriental Clinical Oncology, College of Oriental Medicine, Kyung-Hee University) ;
  • Cheon, Seong-Ha (Division of Hemato-Oncology, Dept. of Internal Medicine, Kyung-Hee University Hospital at Gangdong)
  • 발행 : 2011.03.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

This report documents a case in which the administration of an herbal product, an extract of the lacquer tree, Rhus verniciflua Stokes, as sequential and concurrent treatment with chemotherapy was associated with a long term survival and good quality of life in a patient with metastatic non-small cell lung cancer(NSCLC). A 51-year-old Korean female was referred to the $M{\cdot}{\mu}$ Integrative Cancer Center, East-West Neo Medical centrer, Kyung Hee University for stage IV, metastatic NSCLC. She was treated with aRVS alone for 19 months and then received 1st line paclitaxel/carboplatin combined with aRVS, 2nd line gefitinib, and 3rd line pemetrexed. The number of cycles of pemetrexed administered was seventeen. aRVS was restarted as the 13th pemetrexed was administered. Pemetrexed with aRVS is currently ongoing. This patient has been alive for 41 months, and has been keeping a good performance status so far. We suggest aRVS as sequential and concurrent treatment with chemotherapy is an effective alternative treatment strategy.

키워드

참고문헌

  1. Yoo KY. Cancer control activities in the Republic of Korea. Jpn J Clin Oncol. 2008;38:327-33. https://doi.org/10.1093/jjco/hyn026
  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. CA Cancer J Clin. Cancer statistics. 2008;58:71-96. https://doi.org/10.3322/CA.2007.0010
  3. Stinchcombe TE SM. Considerations for second -line therapy of non-small cell lung cancer. Oncologist. 2008;13:28-36. https://doi.org/10.1634/theoncologist.13-S1-28
  4. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095-103.
  5. Schiller JH HD, Belani CP, Langer C, Sandler A, Krook J, Zhu J, et al; Eastern CooperativeOncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-8. https://doi.org/10.1056/NEJMoa011954
  6. Mok TS WY, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57. https://doi.org/10.1056/NEJMoa0810699
  7. Sandler A GR, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, at al. Paclitaxel -carboplatin alone or with bevacizumab for non -small-cell lung cancer. N Engl J Med. 2006;355:2542-50. https://doi.org/10.1056/NEJMoa061884
  8. Shepherd FA RPJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-32. https://doi.org/10.1056/NEJMoa050753
  9. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Cisplatinversus carboplatin-based chemotherapy in firstline treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99:847-57. https://doi.org/10.1093/jnci/djk196
  10. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:3852-9. https://doi.org/10.1200/JCO.2004.02.109
  11. Pirker R PJ, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, et al, FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;273:1525-31.
  12. Yoo HT RJ. Compendium of prescriptions from the countryside(Hyangyakjipseongbang). Seoul: Hangrimchulpansa; 1977, p. 1433-640.
  13. Choi WC LJ, Lee EO et al. Study on antiangiogenic and antitumor activities of processed Rhus verniciflua Stokes extract. Korean J Oriental Physiol Pathol. 2006;20:1-5.
  14. Kook SH SY, Chung SW, et al. Caspase-independent death of human osteosarcoma cells by flavonoids is driven by p53-mediated mitochondrial stress and nuclear translocation of AIF and endonuclease G. Apoptosis. 2007;12:1289-98. https://doi.org/10.1007/s10495-007-0056-x
  15. Lee JC, Kim J, Jang YS. Ethanol-eluted extract of Rhus verniciflua stokes inhibits cell growth and induces apoptosis in human lymphoma cells. J Biochem Mol Biol. 2003;36:337-43. https://doi.org/10.5483/BMBRep.2003.36.4.337
  16. Lee SH, Kim KS, Choi WC, Yoon SW. Successful outcome of advanced pulmonary adenocarcinoma with malignant pleural effusion by the standardized Rhus verniciflua stokes extract: a case study. Explore (NY). 2009;5:242-4. https://doi.org/10.1016/j.explore.2009.04.001
  17. Lee SK, Jung HS, Eo WK, Lee SY, Kim SH, Shim BS. Rhus verniciflua Stokes extract as a potential option for treatment of metastatic renal cell carcinoma: report of two cases. Ann Oncol. 2010;21:1383-5. https://doi.org/10.1093/annonc/mdq154
  18. Lee SH, Choi WC, Kim KS, Park JW, Yoon SW. Shrinkage of gastric cancer in an elderly patient who received Rhus verniciflua Stokes extract. J Altern Complement Med. 2010;16:497-500. https://doi.org/10.1089/acm.2008.0237
  19. Kim HR, Kim KS, Jung HS, Choi WC, Eo WK, Cheon SH. A case of recurred hepatocellular carcinoma refractory to doxorubicin after liver transplantation showing response to herbal medicine product, Rhus verniciflua Stokes extract. Integr Cancer Ther. 2010;9:100-4. https://doi.org/10.1177/1534735409359772
  20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  21. Richardson MA ST, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000;18:2505-14.
  22. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-smallcell lung cancer. J Clin Oncol. 2002;20:1335-43. https://doi.org/10.1200/JCO.20.5.1335
  23. Hanna N SF, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589-97. https://doi.org/10.1200/JCO.2004.08.163
  24. Chang MH AJ, Lee J, Kim KH, Park YH, Han J, Ahn MJ, et al. The efficacy of pemetrexed as a third-or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. Lung Cancer. 2010;69:323-9. https://doi.org/10.1016/j.lungcan.2009.12.002
  25. Sun JM LK, Kim JH, Kim YJ, Yoon HI, Lee JH, Lee CT, et al. Efficacy and toxicity of pemetrexed as a third-line treatment for nonsmall cell lung cancer. Jpn J Clin Oncol. 2009;39:27-32.